Previous 10 | Next 10 |
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , today anno...
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , announced ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Social media traders on communities such as Reddit’s r/WallStreetBets have had an amazing 2021. All of Wall Street stopped what it was doing to watch the excitement in GameStop (NYSE: GME ), BlackBerry ...
BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , today anno...
BRYAN, Texas, Aug. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System ® , announced today the appo...
– iBio licenses a novel antibody targeting regulatory T cells – – Company secures option to license additional antibodies developed with RubrYc’s predictive algorithms – – iBio acquires an equity stake in RubrYc – SAN ...
3 Hot Biotech Penny Stocks to Know About in August Biotech penny stocks have remained some of the most popular penny stocks to watch throughout the past year and a half. The obvious reason behind this is the impact of the pandemic and the resulting attention on the biotech industry....
MarsBars/E+ via Getty Images IBIO-202, the subunit vaccine candidate developed by iBio (IBIO) against COVID-19 showed a strong and antigen-specific memory T-cell response, the company said. The current commercially available COVID-19 shots targeting the spike protein (“S protein...
BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that ...
iBio (IBIO) announces that it is adding three anti-cancer targets to its pipeline of therapeutic candidates.The company also highlighted that it has entered into a research services agreement with FairJourney Biologics to gain access to novel display technologies and proprietary antibody...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...